A Phase 3 Study of Oral PTH (1-34) for the Treatment of Osteoporosis for the treatment of osteoporosis in comparison with subcutaneous FORTEO (teriparatide, Eli Lilly)

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 22 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Nov 2023 According to an Entera Bio media release, the company is prepared to initiate a pivotal phase 3 study in post-menopausal women with high-risk osteoporosis and no prior fracture.
12 May 2022 According to an Entera Bio media release, company and the FDA agreed upon the production and specifications of the drug components and final product for the Phase 3 study. The Company looks forward to providing further updates related to its productive discussions with the Food and Drug Administration (FDA) in the near term.
17 Feb 2022 According to an Entera Bio media release, data from this trial will be presented at the Aegis Capital Corp. Virtual Conference.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com